Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

and development expenses for the year ended December 31, 2008 totaled $46.5 million compared with $38.9 million in 2007. Research and development expenses were $13.9 million for the three months ended December 31, 2008 compared to $9.3 million for the same quarter the previous year. The increase in expenses was the net result of: achieving full enrolment of clinical sites and patients in the MAESTRO-03 trial; increased costs for the MAESTRO-02 trial as patients enter the trial; reduced costs of the MAESTRO-01 and MINDSET-01 trials as more patients complete these trials; a decrease in drug manufacturing expenses as the manufacture of validation batches is completed; a licensing bonus payment related to the Agreement with Lilly, and; additional expenses related to alliance management and support.

At December 31, 2008, cash and cash equivalents and short-term investments totaled $90.4 million as compared to $37.9 million at December 31, 2007. At December 31, 2008, the Company had working capital of $81.3 million as compared to $32.8 million at December 31, 2007. Management estimates that the current working capital is sufficient for the Company to meet its obligations in respect of the currently initiated clinical trials.

As at December 31, 2008 there were 91,009,323 Class "A" common shares of the Company issued and outstanding.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchan
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Audubon, PA and London (PRWEB) November 21, 2014 ... in December will explore what comes next for ALS research ... clinical sites. , After the Ice Bucket Challenge: Where ... Merit Cudkowicz, Date: Tuesday, 2 December 2014, Time: ... complimentary , Join expert speaker Dr. Merit Cudkowicz, Julianne ...
(Date:11/22/2014)... During his lifetime Richard L. Sharp was ... himself with great people and take risks to achieve ... marveled at his extraordinarily courageous attitude when taking on ... even with his death impending—that’s how he continued looking ... ultimately take his life. , Carrying on Sharp’s relentless ...
(Date:11/22/2014)... MA (PRWEB) November 21, 2014 ... key investors will gather on December 3rd at ... Biotech Conferences series. GeneticRx will take place at ... Medical School and will discuss the present and ... therapy, exon skipping, and gene editing—as well as ...
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), the leading ... methodologies relating to cannabis, today announced that it has ... from an existing stockholder of the Company. , ... from one of our existing stockholders,” stated Mark ... help accelerate our planned expansions into the Connecticut and ...
Breaking Biology Technology:DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2CannLabs Secures $750,000 Line Of Credit 2
... Obstructive ... Sleep Apnea, Advanced ... Employee Productivity; Minimize Litigation Risks, CARLSBAD, Calif., Sept. 5 ... manage was the number,of hours a driver spent behind the wheel. ...
... WEST BRIDGEWATER, Mass., Sept. 5 Pressure,BioSciences, Inc. ... has received,approval to CE Mark the Barocycler NEP2320, ... (PCT) instrument. The,Company also announced that it has ... indicating that the Barocycler NEP2320 has been found ...
... a Proven Leader at Driving Growth, SAN FRANCISCO, ... equity firm that focuses on investments in selected segments,of ... software, today announced the appointment of Michael L. Hurt,to ... Mr. Hurt, CEO,of Altra Industrial Motion (Nasdaq: AIMC ...
Cached Biology Technology:Time For the Trucking and Heavy Machinery Industries to Wake Up! 2Time For the Trucking and Heavy Machinery Industries to Wake Up! 3Time For the Trucking and Heavy Machinery Industries to Wake Up! 4Time For the Trucking and Heavy Machinery Industries to Wake Up! 5Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 2Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 3Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 4Genstar Names Michael Hurt to Its Strategic Advisory Board 2
(Date:11/5/2014)... Santamaria, associate professor of biology in the UTSA ... in the nation selected to receive a two-year ... for Exploratory Research (EAGER). The funding supports President ... researchers to create new technology that will demystify ... complex behaviors in neuroscience are broken into the ...
(Date:11/4/2014)... at the right time might actually help boost a ... help in understanding animal populations, pest control and managing ... the journal Trends in Ecology and Evolution , ... the kind of positive population effect an overall species ... on the size and developmental stage of the creatures ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... "mother of thousands" (Kalanchoe diagremontiana) makes the tiny plantlets that ... ability to make viable seeds, the plant has shifted some ... Neelima Sinha, professor of plant biology at UC Davis. ... that can grow into new plants. But mother of thousands ...
... Integrating silicon microchip technology with a network of tiny ... at The Johns Hopkins University have developed a thumb-size ... In a recent edition of the journal IEEE Transactions ... reported that they had successfully used the micro-incubator to ...
... to be penetrated by metastasizing cancer cells, so a ... block cancers spread, according to researchers at the ANZAC ... of breast cancer metastasis, the researchers found that a ... cancer to target bone. Dietary calcium, they reason, might ...
Cached Biology News:Thumb-size microsystem enables cell culture and incubation 2Thumb-size microsystem enables cell culture and incubation 3Dietary calcium could possibly prevent the spread of breast cancer to bone 2